Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics, Inc.

Unicycive is focused on delivering disease-modifying therapies for major global health issues, particularly in relation to kidney diseases.

Metric
Company Name	Unicycive Therapeutics, Inc.
Symbol	UNCY
MSH ID	COM:UNICYCIVE
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	14
Website	unicycive.com
LinkedIn
Founders

Metric
Market Cap	41.21M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	675K
Revenue (LTM)
Revenue (NTM)
Gross Profit	391K
EBITDA	-20.49M
Operating Income	-20.77M
Net Income	-30.54M
EPS	-1.24
Diluted EPS	-1.24
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	2.93
Operating Profit Margin	106.48
EBITDA Margin	-30.36
Net Profit Margin	136.55
Return on Equity	8.22
Return on Assets	-0.65
Return on Capital Employed	6.21

COM:UNICYCIVE

Unicycive

Last Close

0.53

22/11 21:00

Market Cap

41.21M

Beta: -

Volume Today

872.40K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.84
P/B Ratio	9.50
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	70.54
EV Multiple	-0.69

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle	-865.39
Asset Turnover	0.05

Metric
Operating Cash Flow	-18.28M
Free Cash Flow	-18.30M
Cash Flow to Debt	-0.45
Operating Cash Flow/Sales	79.84
Free Cash Flow Yield	-0.57

Metric
Cash & Equivalents	9.70M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	2.11
Debt to Assets	0.04
Current Ratio	1.20
Quick Ratio	3.37

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	2.09
R&D to Revenue	18.53
SG&A to Revenue	11.78